MSD launches Clostridium difficile antitoxin in the UK
MSD has launched Zinplava in the UK, offering patients a novel therapeutic option for the prevention of Clostridium difficile recurrence.
Read More
Tag: antitoxin
US nod for Merck’s C.difficile antitoxin
The US Food and Drug Administration has cleared Merck’s Clostridium difficile (CDI) recurrence jab Zinplava after having extended the review period by three month.
Read More
US delay to Merck’s C.difficile antitoxin
Merck & Co’s investigational clostridium difficile treatment has been hit with a setback in the US after regulators extended the review time for the drug by three months.
Read More
- NICE backs daratumumab quadruplet for newly diagnosed transplant‑ineligible myeloma
- Anocca doses first patients with precision TCR‑T therapy
- Connecta launches phase 2a trial of neuroplasticity modulator
- Aquipta recommended by NICE for acute migraine treatment
- Talvey accepted for use in Scotland for relapsed and refractory multiple myeloma
